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Abstract:  Alcohol  abuse  is  a  serious  medical  and  social  problem.  Although  light  to 
moderate alcohol consumption is beneficial to cardiovascular health, heavy drinking often 
results in organ damage and social problems. In addition, genetic susceptibility to the effect 
of alcohol on cancer and coronary heart disease differs across the population. A number of 
mechanisms including direct the toxicity of ethanol, its metabolites [e.g., acetaldehyde and 
fatty acid ethyl esters (FAEEs)] and oxidative stress may mediate alcoholic complications. 
Acetaldehyde, the primary metabolic product of ethanol, is an important candidate toxin in 
developing  alcoholic  diseases.  Meanwhile,  free  radicals  produced  during  ethanol 
metabolism and FAEEs are also important triggers for alcoholic damages. 
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1. Introduction 
The alcohol family is comprised of three different members namely methyl alcohol (methanol), 
isopropyl alcohol and ethyl alcohol (ethanol, EtOH or CH3CH2OH). The first two forms of alcohol are 
toxic and prohibited to consume. However, ethanol, or alcohol as commonly called, is an intoxicating 
ingredient  in  beer,  wine  and  other  forms  of  liquor.  Over  centuries,  alcohol  has  become  the  most 
socially-accepted addictive drug worldwide. Alcohol beverages have long been known for their rather 
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important  role  in  social  activities.  Drinking  alcoholic  beverages  is  a  common  feature  of  social 
gatherings. Although light to moderate drinkers tend to display an overall better cardiovascular health 
and longevity compared with abstainers or heavy drinkers [1-4], long-term alcohol misuse or binge 
drinking can result in life-threatening health hazards both physically and mentally. Moreover, genetic 
susceptibility to alcohol-associated risk prevalence of cancer and coronary heart disease differs across 
the population. Therefore, it is recommended that moderate drinking must be individualized to reflect 
the potentially confounding effects of alcohol on several chronic diseases [5]. For example, individuals 
with a high risk of carcinogenesis should abstain from alcohol use [6]. Certain devastating chronic 
diseases such as heart disease [7-9], Alzheimer’s disease [10], stroke [11,12], liver disease [13-15], 
cancer [16-18], chronic respiratory disease [19,20], diabetes mellitus [21-23] and bone disease [24,25] 
may  develop  following  chronic  alcohol  ingestion  and  contribute  to  the  alcoholism-related  high 
morbidity and mortality. In addition to chronic diseases, alcohol abuse may also trigger a cascade of 
acute health problems such as traffic accident-related injuries. Furthermore, social problem can also be 
a  consequence  of  alcohol  abuse  including  domestic  violence,  loss  of  work-place  productivity, 
economic  burden  on  society,  crime  and  public  disorders  [26-29].  With  the  increased  alcohol 
consumption in women and adolescences [30], alcohol-related social and health problems are attracting 
more and more attention.   
To-date,  a  number  of  theories  have  been  postulated  for  the  pathogenesis  of  alcohol-induced 
complications  including  direct  toxicity  of  ethanol  and  its  metabolites  [31],  oxidative  stress, 
accumulation of fatty acid ethyl esters [32] as well as modifications of lipoprotein and apolipoprotein 
particles [33]. In particular, acetaldehyde, the primary metabolic product of ethanol, is thought to be a 
candidate  toxin  and  plays  a  pivotal  role  in  priming  and  developing  alcoholism  [34].  Genetic 
polymorphism in alcohol dehydrogenase (ADH) [35] and aldehyde dehydrogenase (ALDH) [36,37], 
the two key enzymes responsible for ethanol/acetaldehyde metabolism, is involved in the susceptibility 
to  alcoholism  and  alcohol-related  organ  damage  and  diseases.  Ethanol  elimination  occurs  through 
oxidation to acetaldehyde and acetate by way of ADH and ALDH, respectively. Different levels of 
blood acetaldehyde are shown in different genotypic verifications in the ADH or ALDH gene following 
alcohol  intake  [37],  thus  predisposing  these  individuals  to  alcohol  damage,  and  the  degrees  of 
polymorphism differs depending on racial and ethnic groups [38]. 
2. Alcohol and Human Health 
Since the beginning of last century, a number of studies have demonstrated that light to moderate 
alcohol consumption is associated with better cardiovascular health and longevity outcome compared 
with either abstainers or heavy drinkers [34,39]. One of the earliest scientific studies on the subject 
appeared in the Journal of the American Medical Association in 1904. In addition to reducing the risk 
of heart attacks, e.g., coronary heart disease (CHD), ischemic heart disease, atherosclerosis, angina 
pectoris  [40-44],  light  to  moderate  drinking  is  also  generally  beneficial  in  minimizing  the risk of  
stroke [45], peripheral artery disease [46], hypertension [35,47], liver disease [48], Alzheimer's disease, 
Parkinson's  disease,  diabetes  [49-51],  rheumatoid  arthritis  [52],  bone  fractures  and  
osteoporosis [53,54], digestive ailments [55], stress and depression [56], renal cell carcinoma [57], 
pancreatic  cancer  [58],  duodenal  ulcer  [59],  macular  degeneration  [60],  hearing  loss  [61],  Int. J. Environ. Res. Public Health 2010, 7                 
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gallstones  [62],  poor  physical  condition  in  the  elderly  [63]  and  common  cold  [64].  Although  the 
benefits and risks associated with light to moderate drinking have gained increasing attention in recent 
years from both researchers and the general public [39], no universal definition of moderate drinking 
has been established. The currently accepted definition for moderate drinking employs pure ethanol 
contained in “one drink” as a unit quantity to evaluate the amount consumed in a specific time period 
(e.g., USA and Canada, 12 or 14 g; Australia, 10 g; UK and Ireland, 8 g; Italy and Spain, 10 g; 
Denmark and France, 12 g; Japan, 20 g) [65]. There is also an indication to use 24 g ethanol, or two US 
standard drinks or less in a day, as the moderate alcohol intake [66].  
Despite  the  beneficial  effects  of  light  to  moderate  alcohol  intake,  an  ample  of  clinical  and 
experimental evidence has demonstrated the concordant J or U-shaped associations between alcohol 
intake and a variety of adverse health outcomes [1]. Long-term alcohol misuse or heavy drinking not 
only failed to improve the health outcome but also enhanced the risk of various human diseases such as 
those mentioned previously. Binge drinking may cause detrimental damage to human organs including 
brain, liver, heart, lung, skeletal muscle and bones. For example, the brain may be affected resulting in 
confusion  and  memory  loss  [67-69].  The  liver,  the  main  site  of  ethanol  oxidation,  is  extremely 
vulnerable to alcoholic damage [70,71], leading to cirrhosis, a severe form of liver disease and a major 
cause  of  death  in  the  United  States  [72,73].  Excessive  ethanol  consumption  also  results  in 
cardiovascular  disease  (the  number  one  cause  of  death  in  the  US),  including  ventricular  
dysfunction  [74,75],  dilated  cardiomyopathy  [74],  ventricular  arrhythmias  [76],  myocardial  
fibrosis [77] as well as enhanced risk of stroke and hypertension [78,79]. These morphological and 
functional defects of myocardium will eventually result in heart failure.  
It should be emphasized that moderate drinking is recommended to be individualized to reflect the 
potentially  competing  or  confounding  effects  of  alcohol  on  certain  chronic  diseases  [5].  It  was 
indicated that moderate drinking had no beneficial effect on mortality in young adults (premenopausal 
women and men <40 years of age). Nonetheless, it is speculated that moderate drinking in young 
adulthood  may  dampen  the  risk  of  heart  diseases  later  on  in  life.  In  certain  populations,  such  as 
pregnant women, heavy drinkers and those on medication that may interact adversely with alcohol, the 
risk of alcohol consumption, even in the form of moderate ingestion, outweighs potential benefits [80]. 
Somewhat along this line, Sun and colleagues found that light to moderate alcohol use may provide the 
optimal benefit in older adults with poor health condition [81]. Evidence from the 2007 World Cancer 
Research Fund and American Institute for Cancer Research summary report recommended individuals 
with high risk of cancer are not recommended to drink alcoholic drinks despite the fact that modest 
amounts of alcoholic drinks are likely to reduce the risk of coronary heart disease [6]. Evidence from 
Allen and colleagues revealed that moderate alcohol use may particularly increase the risk of certain 
cancers such as breast and liver cancers while reducing the risk of some other cancers in women. 
Moreover,  the  alcohol-associated  risk  for  upper  aerodigestive  tract  cancer  (oral  cavity,  esophagus, 
larynx and pharynx) was confined in active smokers, with little effect of alcohol use in never and past 
smokers [82]. Nonetheless, it is rather difficult to conclude whether the increased risk of cancer was 
due to alcohol intake or smoking since the two behaviors tend to be concurrent quite often. Although 
further work is still needed to fully consolidate the correlation between cancer prevalence and moderate 
alcohol intake, the American Cancer Society recommends limited alcohol use in both men (<2 drinks Int. J. Environ. Res. Public Health 2010, 7                 
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per  day)  and  women  (<1  drink  per  day).  Taken  together,  whether  moderate  alcohol  use  plays  a 
protective, unrelated or adverse role in human health is still controversial, depending heavily on age, 
gender and type of alcoholic beverage.  
3. Mechanisms of Alcoholic Diseases  
A  number  of  mechanisms  have  been  postulated  for  the  pathogenesis  of  alcoholic  injuries  and 
diseases, including toxicity of ethanol and its metabolite acetaldehyde, the primary metabolic product 
of ethanol. In addition, oxidative stress, accumulation of fatty acid ethyl esters and modification of 
lipoprotein  and  apolipoprotein  particles  [33]  also  contribute  to  alcohol-associated  complications. 
Although alcohol exposure is associated with multiple toxic effects on various organs through different 
mechanisms, two main categories are worth considering: acetaldehyde-related and non-acetaldehyde-
related mechanisms. 
 
3.1. Mechanism of Alcohol Metabolism 
 
Ethanol metabolites and oxidative stress (through accumulation of reactive oxygen species—ROS) 
are  thought  to  be  the  main  causes  of  alcohol-induced  organ  damage.  A  majority  of  ethanol  is 
metabolized in the cytoplasm of the liver by the enzyme ADH to produce acetaldehyde, which is then 
further metabolized to another less active byproduct, acetate, by ALDH [83]. The two enzymatic steps 
both  require  NAD  as  the  hydrogen  acceptor.  The  enzymes  cytochrome  P450  2E1  (CYP2E1)  and 
catalase also break down alcohol to acetaldehyde. However, CYP2E1, the enzyme in the E subfamily 
of the second family P450s, becomes active only after a person has consumed large amount of alcohol. 
Under normal conditions, CYP2E1 accounts for less than 10% of ethanol metabolism. Catalase also 
metabolizes only a small fraction of alcohol without requiring NAD as a cofactor [83]. All these ways 
of metabolizing ethanol result in acetaldehyde, a primary metabolic product of alcohol. Acetaldehyde is 
a  key  generator  of  free  radicals  and  a  known  carcinogen.  Moreover,  high  levels  of  NADH  in 
mitochondria can cause an increase in the number of superoxide (O2
-) free radicals leading to the 
formation of hydroxyl radicals (OH
-), lipid peroxidation and damage to mitochondria DNA [84]. High 
levels of free radicals diminish or impair the antioxidant homeostasis, leading to tissue damage. In 
addition, ethanol may induce up to a 10-fold up-regulation of CYP2E1 in the liver, which may be 
responsible  for  alcoholism-triggered  oxidative  damage  [85-87].  Evidence  has  indicated  that  small 
amounts of alcohol may be removed via interaction with fatty acids to form fatty acid ethyl esters 
(FAEEs), the latter has been shown to contribute to damage to the heart, liver and pancreas [88,89]. 
 
3.2. Acetaldehyde-Related Mechanism in Alcohol-Induced Damages 
 
Acetaldehyde, an organic chemical compound (CH3CHO or MeCHO), is an active metabolite that 
induces a range of toxic, pharmacological and behavioral responses. Although acetaldehyde is only 
short-lived prior to its breakdown into acetate, it possesses the ability to elicit overt cellular and tissue 
damage.  The  liver  is  often  considered  the  primary  site  of  oxidation  [90],  although  other  organs 
including the heart, pancreas, gastrointestinal tract and the brain, may also participate in the ethanol Int. J. Environ. Res. Public Health 2010, 7                 
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metabolism to form acetaldehyde [16,83,88,89]. Acetaldehyde causes mitochondrial dysfunction and in 
turn compromises acetaldehyde metabolism to result in the accumulation of acetaldehyde, leading to a 
vicious cycle. Acetaldehyde may also react with amino, hydroxyl, and sulfhydryl groups to interfere 
with  or  modify  the  structure  and  function  of  macromolecules  in  the  body,  such  as  proteins  and  
enzymes [89,91].  
Accumulating evidence suggested that acetaldehyde plays a key role in the pathogenesis of alcoholic 
cardiomyopathy [92-97]. In particular, acetaldehyde has been shown to lead cardiac hypertrophy or 
dilated cardiomyopathy associated with significant increase in the hypertrophic marker skeletal actin 
and  ANF  [97].  Data  from  our  laboratory  have  shown  that  acetaldehyde  compromises  myocardial 
excitation-contraction  coupling,  sarco  (endo)  plasmic  reticulum  [42]  Ca
2+  release  and  cardiac 
contractile  function  [34,75,98,99].  The  mechanism  underlying  acetaldehyde-induced  myocardial 
depression may be due, in part, to either reduced Ca
2+ entry through voltage-dependent Ca
2+ channels 
and/or depression of sarcoplasmic reticular Ca
2+ release [75]. Our previous study showed that alcohol 
intake significantly reduced expression of the intracellular Ca
2+ cycling proteins SERCA2a, Na
+-Ca
2+ 
exchanger  and  phospholamban  in  cardiomyocytes  without  overt  change  in  the  SERCA2a-to-
phospholamban ratio [100]. Although the precise mechanism behind alcohol-induced change in the 
intracellular  Ca
2+  regulatory  proteins  is  not  fully  clear,  acetaldehyde  is  believed  to  play  a  role. 
Acetaldehyde  was  recently  suggested  to  function  as  a  ryanodine  receptor  activator  to  leading  to 
disturbed cardiac contractile function [101] and elevated intracellular Ca
2+ levels [102]. Acetaldehyde 
stimulates the release of signaling molecules (epinephrine, norepinephrine, histamine and bradykinin) 
and leads to the cardiovascular symptoms of the alcohol sensitivity reaction such as vasodilation and 
facial flushing. It also associated with abnormal heart beat and blood pressure [103]. As the major 
metabolite of ethanol, acetaldehyde production results directly in the formation of free radicals through 
aldehyde oxidase and xanthine oxidase-associated oxidation and indirectly in decreased antioxidant 
defenses (e.g., GSH levels) [34,104,105], resulting in oxidative stress. Acetaldehyde can also induce 
apoptosis  via  activation  of  stress  signaling  such  as  c-Jun  phosphorylation  [34,106,107].  This  is 
supported by our experimental findings of elevated TUNEL-positive apoptotic cells in ADH murine 
hearts following ethanol challenge.  
In  addition  to  direct  cytotoxicity,  acetaldehyde-associated  organ  damage  may  also  be  mediated 
through inflammatory cytokines (e.g., tumor necrosis factor and the interferons), as well as the binding 
capability to certain proteins [108-110]. In addition to direct organ damage, acetaldehyde may also be 
responsible  for  certain  behavioral  and  physiological  effects  previously  attributed  to  alcohol.  For 
example,  when  acetaldehyde  is  administered  to  lab  animals,  it  leads  to  uncoordination,  memory 
impairment,  and  sleepiness,  effects  often  associated  with  alcohol  ingestion  [103].  Moreover,  the 
acetaldehyde-DNA  binding  has  been  considered  to  promote  carcinogenesis  in  alcohol-dependent 
individuals [111]. Similarly, formation of crotonaldehyde [66] from acetaldehyde is also known as a 
potentially  carcinogenic  pollutant  [112].  Paradoxically,  acetaldehyde  may  also  contribute  to  the 
beneficial  effect  following  light  to  moderate  alcohol  intake.  It  was  reported  that  attachment  of 
acetaldehyde  to  a  model  Amadori  product  produces  a  chemically  stabilized  complex  that  cannot 
rearrange  and  progress  to  formation  of advanced glycation endproducts,  or AGEs [113]. Amadori 
products typically arise from the nonenzymatic addition of sugars to protein amino groups and are the Int. J. Environ. Res. Public Health 2010, 7                 
 
 
1290 
precursors to the irreversibly bound, crosslinking moieties of AGEs, which are detrimental to health. 
Therefore,  acetaldehyde-induced  protein  adduct  may  contribute  to  the  beneficial  effect  of  light  to 
moderate alcohol intake, or the so-called “French paradox” by inhibiting advanced glycation. 
 
3.3. Non-Acetaldehyde-Related Mechanism in Alcohol-Induced Damages 
 
Recent  evidence also  indicates the contribution  of acetaldehyde-independent mechanisms to the 
pathogenesis  of  alcoholic  diseases.  For  example,  ethanol  may  elicit  direct  toxic  effects  on  the 
cardiovascular  system  or  alter  neurohumoral  and/or  hormonal  regulation  of  cardiac  function  [78]. 
Certain metabolic product of ethanol such as fatty acid ethyl esters (FAEEs) may also interfere with the 
physiological function of the heart independently of acetaldehyde. The formation of FAEEs in the heart 
is  an  example  of  a  non-oxidative  metabolism  of  alcohol,  and  is  distinguished  from  the  oxidative 
metabolism of alcohol in the liver. FAEEs may prove to be the first link between the ingestion of 
alcohol and the development of alcohol-induced heart muscle disease. Although the amount of fatty 
acids in heart muscle is small, following consumption of alcohol, FAEEs concentration in the human 
myocardium  can  accumulate  115,000-fold  higher  than  in  the  normal  heart  muscle  [114,115]. 
Accumulation of fatty acid ethyl esters is capable of reducing the respiratory control ratio index of 
coupling of oxidative phosphorylation and maximal rate of oxygen consumption, and accounts for 
impaired  mitochondrial  function and inefficient energy production  associated with  toxic effects  of 
ethanol on the heart [115].  Data from our group also suggested that acetaldehyde-induced cardiac 
mechanical dysfunction may be ablated by folate or thiamine supplementation [116,117], suggesting a 
possible  interaction  between  acetaldehyde-induced  cardiac  toxicity  and  nutritional  status.  This  is 
somewhat  consistent  with  the  favorable  response  of  patients  with  alcoholic  cardiomyopathy  to 
thiamine and nutrition treatment [118].   
Meanwhile, ethanol metabolism also produces stable and unstable protein adducts. For example, 
acetaldehyde binds to some proteins and becomes a Schiff base, thus forming protein-acetaldehyde 
adducts.  Furthermore,  the  lipid  peroxide-derived  aldehydes  such  as  malondialdehyde  (MDA)  and  
4-hydroxynonenal may eventually form stable hybrid adducts by potential protein modifications. These 
multiple adducts were shown to have a cadre of inverse effects on the cells of the immune system and 
involved in the development of alcoholic organ disease, including liver, heart and brain [110,119].   
 
3.4. Genetic Polymorphisms of Alcohol Metabolizing Enzymes 
 
Alcoholism  has  been  considered  to  be  associated  with  different  genetic  factors  in  alcohol 
metabolism in different ethnic groups. Studies have identified numerous functional polymorphisms in 
genes encoding enzymes for ethanol metabolism. According to recent studies, the human ALDH gene 
superfamily comprises 19 genes encoding enzymes critical for NAD (P)
+—dependent oxidation of 
endogenous and exogenous aldehydes [120]. Meanwhile, there are at least seven genes in the ADH 
family [121]. ADH2, ADH3, and ALDH2 are thought to be the pivotal genetic determinants in ethanol 
metabolism and alcoholism in humans.  Int. J. Environ. Res. Public Health 2010, 7                 
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Within the nine major members of ALDH families, mitochondrial ALDH2 has a rather unique role 
in aldehyde detoxification [122]. Deficiency in ALDH2 expression and/or activity is responsible for 
facial flushing and other vasomotor symptoms following alcohol ingestion. In addition, findings from 
Kawamoto’s group indicated that deficiency in ALDH2 enzymatic activity inhibits acetate formation 
via acetaldehyde [123]. Prevalence of the ALDH2*1 allele is associated with alcoholism. Deficiency in 
ALDH2 due to point mutation in the active ALDH2*1 gene, significantly alters blood acetaldehyde 
levels and vulnerability for alcoholism [124]. However, ALDH2*2, which is dominant over ALDH2*1, 
encodes  a glutamate to lysine substitution at residue 487 in the mature enzyme, resulting in a loss of 
enzymatic activity [122]. In addition, individuals carrying the ADH2*2 allele display slightly facilitated 
alcohol  metabolism  due  to  higher  enzyme  activity  compared  with  ADH2  *1  encoding  
populations [125].  
Research reported that the allele frequencies of the genes ADH2*2 and ALDH2*2 were lower in 
Northwest Coast Amerindians, Africans, Europeans and Australian Aborigines than South America 
Indians and Asians including Chinese, Japanese and Koreans [125-127]. The ALDH2*2 allele encodes 
an inactive subunit of ALDH2, which consists of four subunits, and ALDH2 shows lack of activity 
when even one inactive subunit protein is included [128]. Therefore, Asians always cannot drink a 
great amount of alcohol as compared with Caucasians.  
Some studies also indicated that those who carry ALDH2*2 alleles were strikingly responsive to a 
small amount of alcohol. Large accumulation of acetaldehyde in the blood of these people produces a 
pattern of uncomfortable  effects  such as  increasing skin temperature and facial flushing, dropping 
blood pressure, nausea, headache, palpitations and bronchoconstriction [103]. Of certain significance, 
some researchers suggested that acetaldehyde causing these symptoms may provide a protective role 
against heavy drinking intake, otherwise, alcoholism or worse outcome [36]. It has been suggested that 
the mutant ALDH2 gene of ALDH2*2/2 may protect against development of alcohol dependence and 
alcohol-related  disease  [129].  Nonetheless,  this  sort  of  epidemiological  study  fails  to  offer  direct 
evidence regarding the role of acetaldehyde on cardiac function due to intolerance to alcohol among 
these  individuals  with  genetic  polymorphisms  [124].  Our  recent  observation  from  animal  study 
provided some convincing evidence regarding the role of ALDH2 in ethanol-induced cardiac toxicity. 
Overexpression of ALDH2 was found to be cardioprotective against acute ethanol-induced cardiac 
toxicity, possibly through inhibition of protein phosphatases. Our data further revealed that enhanced 
activation of Akt and AMPK, and subsequently, inhibition of Foxo3, apoptosis, and mitochondrial 
dysfunction  may  play  a  pivotal  role  in  ALDH2  overexpression-induced  cardioprotection  against 
ethanol toxicity [130]. 
Alcoholism is a multifactorial disease including a complex mode of hereditary, psychological and 
social factors. More in depth genetic association studies is warranted to further identify and consolidate 
the genetic risk factors for alcoholism. Furthermore, according to the differing polymorphisms among 
racial populations, effective measures can be appropriately taken for the studies. 
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4. Alcohol-induced Social Problems and Effective Ways to Reduce Alcohol Abuse  
 
Alcohol abuse and addiction are not only an individual problem but also a social problem. Alcohol 
abuse is closely associated with the society such as due to car accidents, social violence, broken homes, 
productivity losses, child abuse and any other crimes. Underage drinking is another serious public 
health  concern  in  children  and  adolescents  [131].  Researchers  have  suggested  that  people  with  a 
psychiatric  condition  called  antisocial  personality  disorder  may  be  particularly  susceptible  to  
alcohol-related aggression [27]. Alcohol may also affect female reproductive function at several stages 
of life. It has been shown to elicit a detrimental effect on puberty, to disrupt normal menstrual cycle 
and to alter hormonal levels in postmenopausal women. In addition, alcohol abuse also increases the 
economic burden on society [26,29]. Certain strategies were reported to reduce alcohol abuse, such as 
increased taxes and prices of alcoholic beverages, raising the Minimum Legal Drinking Age, setting 
maximum blood alcohol concentration (BAC) limits for drivers under 21, making warning labels on 
containers of alcoholic beverages, as well as community and educational interventions, e.g., alcohol 
misuse prevention study (AMPS) and drug abuse resistance education (DARE).  
 
5. Conclusion 
 
Given  that  alcohol  drinking-induced  effects  may  exhibit  great  individual  variation,  it  is  rather 
cumbersome to figure out where the line is between social drinking and problem drinking. Chronic 
alcohol ingestion or binge drinking may trigger detrimental bodily damage, which is heavily influenced 
by many interconnected factors such as races, genetics, environment and the emotional health. It is 
generally accepted that light to moderate alcohol consumption is beneficial to reduce the risk of some 
human diseases, although it may increase the risk prevalence for certain cancers especially in women. 
In addition, heavy drinking has been consistently found harmful and dangerous (with lethal damage 
such as cancer, heart and liver disease). Moreover, the social consequences of alcohol abuse can be just 
as devastating. In particular, the emerging trend of more harmful and risky drinking among young 
people and among women may have a severe health outcome [132]. It is essential to understand the 
drinking problems,  the definition of moderate drinking, alcoholism and alcohol abuse. In order to 
minimize the harmful sequelae of alcohol use, it is also important to raise awareness in individual’s 
genetic trait in alcohol metabolizing enzymes ADH and ALDH, and then to apply corresponding and 
necessary measures (for example delay the drinking onset age) [133] to minimize the alcoholic injury.  
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